UBS Reiterates Buy Rating on Cencora Inc (COR)

UBS analyst Kevin Caliendo reiterated a Buy rating and $410.00 price target on Cencora Inc (NYSE: COR).

The analyst commented, "Cencora announced an agreement to acquire EyeSouth Partners' retina business for $1.1B. The deal will be funded using existing credit facilities and cash and is expected to slightly accretive to adjusted EPS in the first 12 months following the close. The company has not embedded any accretion into fiscal 2026, which was reiterated along with this morning's announcement. Details are limited but we understand that acquired retina practices represent a subset of EyeSouth Partners' 400 providers today (the tally includes many general opthalmologists however). In speaking with Cencora management, we understand that the deal will be synergistic to the existing RCA business with all providers being onboarded into the MSO and potential inclusion in related clinical trials. For context, within opthalmology, retina practices tend to drive higher drug usage, which when considering the volume of opthalmology drugs in both the branded and biosimilar pipeline, make for an attractive therapeutic category."

For an analyst ratings summary and ratings history on Cencora Inc click here. For more ratings news on Cencora Inc click here.

Shares of Cencora Inc closed at $320.61 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Darling Ingredients receives US patent for blood glucose collagen peptide
• Citi Resumes Sherwin-Williams (SHW) at Buy